8-K: Canopy Growth Narrows Q3 Loss, Boosted by Canada Cannabis

Canopy Growth Corporation reported a 49% year-over-year reduction in net loss for Q3 FY2026, driven by strong Canadian cannabis sales and cost savings.

Summary

• Consolidated net revenue in Q3 FY2026 was $75M, flat compared to the three months ended December 31, 2024 (Q3 FY2025).
• Cannabis net revenue in Q3 FY2026 was $52M, representing an increase of 4% compared to Q3 FY2025.
• Canada medical cannabis net revenue increased 15% to $23M, and Canada adult-use cannabis net revenue increased 8% to $23M.
• International markets cannabis net revenue decreased 31% year-over-year due to supply chain challenges in Europe but increased 22% sequentially.
• Storz & Bickel net revenue was $23M, increasing 45% sequentially but decreasing 9% year-over-year.
• Net loss in Q3 FY2026 narrowed by 49% year-over-year to $62.6M.
• Adjusted EBITDA loss in Q3 FY2026 narrowed 17% year-over-year to $3M, marking the third consecutive quarter of improvement.
• Free cash outflow improved year-over-year from $28M in Q3 FY2025 to $19M in Q3 FY2026.
• The Company captured $29M of annualized SG&A savings since March 1, 2025.
• The acquisition of MTL Cannabis remains on track to close in the current quarter.
• A strategic recapitalization completed in January 2026 further strengthened the balance sheet, extending maturity dates for all outstanding indebtedness to 2031.
• The Company reported $371M in cash and cash equivalents with a net cash position of $146M at December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, demonstrating significant progress in cost reduction and narrowing losses, particularly in the Canadian market, alongside a strengthened balance sheet.

Positives

• Net loss narrowed by 49% year-over-year to $62.6M, demonstrating significant improvement in financial performance.
• Adjusted EBITDA loss narrowed by 17% year-over-year to $3M, representing the third consecutive quarter of improvement.
• Canada medical cannabis net revenue increased 15% to $23M, driven by an increase in insured patients and order sizes.
• Canada adult-use cannabis net revenue increased 8% to $23M, primarily due to growth in infused pre-roll joints and new AllInOne vapes.
• International markets cannabis net revenue increased sequentially by 22% compared to Q2 FY2026, indicating improving supply chain conditions in Europe.
• Storz & Bickel net revenue increased 45% sequentially, with the new VEAZY™ vaporizer becoming the Company's best-selling device with the fastest ramp to 20,000 units sold.
• SG&A expenses, excluding acquisition, divestiture, and other costs, decreased 12% year-over-year, contributing to $29M in annualized savings since March 1, 2025.
• Free cash outflow improved year-over-year from $28M in Q3 FY2025 to $19M in Q3 FY2026.
• The Company maintains strong financial strength with $371M in cash and cash equivalents and a net cash position of $146M at December 31, 2025.
• A strategic recapitalization completed in January 2026 strengthened the balance sheet by extending maturity dates for all outstanding indebtedness to 2031.

Negatives

• Consolidated net revenue was flat year-over-year at $75M, indicating a lack of overall top-line growth.
• International markets cannabis net revenue decreased 31% year-over-year, primarily due to supply chain challenges in Europe.
• Storz & Bickel net revenue decreased 9% year-over-year, attributed to lapping strong sales and continued consumer economic uncertainty.
• Consolidated gross margin decreased 300 basis points to 29% in Q3 FY2026 compared to 32% in Q3 FY2025.
• Cannabis gross margin decreased from 28% in Q3 FY2025 to 25% in Q3 FY2026, primarily due to lower international sales and a change in sales mix.
• Storz & Bickel gross margin decreased from 40% in Q3 FY2025 to 37% in Q3 FY2026, due to lower sales and increased tariffs on imports into the United States.
• Selling, General and Administrative (SG&A) expenses increased 7% year-over-year as reported, despite reductions when excluding certain costs.

Risks

• Uncertainty regarding the application of U.S. state and federal law to cannabis and hemp (including CBD) products and the scope of any regulations by U.S. regulatory agencies.
• Risks that the Company may be required to write down intangible assets, including goodwill, due to impairment.
• The Company's ability to refinance debt as and when required on terms favorable and to comply with covenants contained in debt facilities and instruments.
• The impacts of the Company's strategy to accelerate entry into the U.S. cannabis market through the creation of Canopy USA.
• Risks that the Huneeus 2017 Irrevocable Trust's future ownership interest in Canopy USA is not quantifiable, and the Trust may have significant ownership and influence over Canopy USA.
• Risks in the event that Acreage Holdings, Inc. and Wana Wellness, LLC cannot satisfy their debt obligations as they become due.
• Volatility in and/or degradation of general economic, market, industry or business conditions, including tariffs, inflation, interest rates, and trade policy.
• Risks relating to the evolving regulatory landscape in the United States and current and future operations in emerging markets.
• Compliance with applicable environmental, economic, health and safety, energy and other policies and regulations, particularly health concerns with respect to vaping and the use of cannabis products.
• Risks and uncertainty regarding future product development and changes in regulatory requirements.
• Reliance on licenses issued by and contractual arrangements with various federal, state and provincial governmental authorities.
• Inherent uncertainty associated with projections and future levels of revenues and the impact of increasing levels of competition.
• Third-party manufacturing and transportation risks.
• Exposure to risks related to an agricultural business, including wholesale price volatility and variable product quality.
• Risks relating to inventory write-downs and the Company's ability to manage disruptions in credit markets or changes to credit ratings.
• The potential effects of judicial, regulatory or other proceedings, litigation or threatened litigation or proceedings, or reviews or investigations, on the business.
• Risks associated with divestment and restructuring, and risks related to stock exchange restrictions.
• Risks related to the protection and enforcement of intellectual property rights.
• Risks related to the Company's exchangeable shares having different rights from common shares and the potential absence of a trading market for them.

Future Outlook

Canopy Growth aims to achieve positive Adjusted EBITDA during fiscal 2027, supported by right-sizing its cost structure and expected growth across core businesses. The acquisition of MTL Cannabis is expected to strengthen its global cannabis platform, and the company continues to seek additional efficiencies beyond the $29M in annualized savings already captured. The company also anticipates the final tranche closing for the acquisition of Jetty and the issuance of additional common shares to satisfy deferred and/or option exercise payments to Wana and Jetty shareholders.

Management Comments

• "The third quarter of fiscal 2026 reflects improving fundamentals and a more focused, integrated operating model across the business, led by strength in Canada. As we continue sharpening execution and move toward closing the acquisition of MTL Cannabis, we see a clear opportunity to further strengthen our platform over time." Luc Mongeau, Chief Executive Officer
• "The decisive cost reduction actions that we have taken to date in fiscal 2026 have strengthened our current year financial performance and will ensure we are well positioned as we close out the fiscal year. With the right-sizing of our cost structure and the expected growth across our core businesses, we are confident that we can achieve our goal of delivering positive Adjusted EBITDA during fiscal 2027." Tom Stewart, Chief Financial Officer

Industry Context

StockSavvy.ai notes that Canopy Growth's performance reflects a broader trend in the Canadian cannabis market where established players are consolidating and focusing on high-margin product segments like infused pre-rolls and vapes. The sequential improvement in international sales, despite year-over-year declines, suggests a potential stabilization or recovery in European supply chains, a common challenge for global cannabis operators. The emphasis on cost reduction and a clear path to positive Adjusted EBITDA in fiscal 2027 aligns with investor demands for profitability in a maturing industry, contrasting with earlier growth-at-all-costs strategies.

Comparison to Industry Standards

• Canopy Growth's 8% growth in Canada adult-use cannabis revenue to $23M, driven by infused PRJs and AIO vapes, indicates effective product innovation and market penetration in a competitive landscape, potentially outperforming some peers struggling with market saturation.
• The 15% increase in Canada medical cannabis revenue to $23M, attributed to insured patients and increased order sizes, suggests a strong patient retention and acquisition strategy, which is a key differentiator in the medical segment compared to recreational markets.
• The 31% year-over-year decline in international cannabis revenue, while sequentially improving by 22%, highlights ongoing global supply chain vulnerabilities that many international cannabis companies, such as Aurora Cannabis or Tilray, have also faced, though the sequential recovery is a positive sign.
• Storz & Bickel's VEAZY™ vaporizer becoming the best-selling device with the fastest ramp to 20,000 units sold demonstrates strong product acceptance and innovation in the vaporization device market, potentially setting a new benchmark for device launches in the sector.

Legal Proceedings

• Litigation costs and recoveries associated with previously divested businesses are included in SG&A expenses.
• The Company faces risks related to the resolution of litigation and other legal and regulatory proceedings, reviews, and investigations.

Related Party Transactions

• The acquisition of additional Class A shares of Canopy USA in connection with an investment by the Huneeus 2017 Irrevocable Trust in the aggregate amount of up to US$20 million.

Stakeholder Impact

• Shareholders: Potential for improved financial performance (narrowing losses, positive Adjusted EBITDA target) and a strengthened balance sheet could lead to increased shareholder value. Future share issuances for Wana/Jetty payments could lead to dilution.
• Employees: Reductions in headcount contributed to SG&A savings, indicating potential job impacts.
• Customers: Improved product offerings (infused PRJs, AIO vapes, VEAZY™ vaporizer) and strengthened engagement with retailers aim to enhance customer experience and product availability.
• Creditors: Strategic recapitalization extending debt maturities to 2031 significantly reduces near-term refinancing risk.

Next Steps

• Closing the acquisition of MTL Cannabis in the current quarter.
• Achieving positive Adjusted EBITDA during fiscal 2027.
• Continuing to look for additional efficiencies beyond the $29M in annualized savings.
• Final tranche closing in connection with the acquisition of Jetty pursuant to the exercise of the option to acquire Jetty.
• Issuance of additional common shares to satisfy any deferred and/or option exercise payments to the shareholders of Wana and Jetty.
• Acquisition of additional Class A shares of Canopy USA in connection with the investment by the Huneeus 2017 Irrevocable Trust.

Key Dates

Recommendation

The filing shows significant operational improvements, particularly in cost control and narrowing losses, and a strengthened balance sheet through debt recapitalization. However, consolidated revenue remains flat, and international sales faced headwinds. While the path to positive Adjusted EBITDA in FY2027 is encouraging, the cannabis industry still faces regulatory uncertainties and intense competition. The stock warrants a 'hold' as the company executes on its strategy, with potential for an upgrade if sustained revenue growth accompanies profitability.

Keywords

Canopy Growth, Cannabis, Financial Results, Q3 FY2026, Earnings, Canada Cannabis, Medical Cannabis, Adult-Use Cannabis, Storz & Bickel, Adjusted EBITDA, Net Loss, Supply Chain, MTL Cannabis, Recapitalization, Vaporizer, VEAZY, SEC Filing, 8-K